Calithera Biosciences Inc. (CALA) 12.93 $CALA Calithera

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 10:06 PM

Calithera Biosciences Inc. (CALA) 12.93 $CALA

Calithera Biosciences Announces Clinical Data Presentation at ASCO 2015
GlobeNewswire - Wed Apr 22, 8:00AM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that clinical data for its lead drug candidate CB-839, the Company's novel, orally bioavailable glutaminase inhibitor, will be presented at the 51 Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 29 to June 2, 2015 in Chicago, Illinois. Clinical results to be presented include updated data from Calithera's Phase I trial in solid tumors. Calithera will hold an investor and analyst briefing Saturday, May 30, 2015 in Chicago, Illinois at 6:30 p.m. CT.
CALA: 12.93 (-1.06)

Calithera Biosciences Highlights Results From Six Preclinical Abstracts at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Tue Apr 21, 6:45AM CDT
-Potential Biomarker Response to CB-839 Among KRAS and EGFR Mutant Cell Lines
CALA: 12.93 (-1.06)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT

SPPR: 2.55 (-0.16), FNRG: 3.11 (-0.86), BIOC: 3.15 (+0.02), NVGN: 7.40 (-0.30), AMPE: 2.89 (+0.20), TRIL: 20.67 (-2.53), CZR: 9.68 (-0.24), TLOG: 4.70 (-0.21), BCLI: 4.29 (-0.09), STDY: 10.10 (+0.11), GENE: 4.88 (-0.05), FARO: 44.64 (-0.93), ICON: 27.06 (+0.45), XXII: 1.50 (+0.04), XBIT: 27.55 (+0.18), UEC: 2.12 (+0.29), COOL: 1.40 (-0.21), CALA: 12.93 (-1.06), WPCS: 3.71 (-0.17), VIMC: 13.42 (+1.31)

BUYINS.NET: CALA SqueezeTrigger Price is $18.90. There is $860,475 That Short Sellers Still Need To Cover.
M2 - Wed Apr 15, 2:56AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Catalina Lighting Inc (NASDAQ:CALA) in real time and just received an alert that CALA is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 44700 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $18.90. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
CALA: 12.93 (-1.06)

Calithera Biosciences to Present at the 14th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 09, 8:05AM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the 14 Annual Needham Healthcare Conference. William D. Waddill, Senior Vice President and Chief Financial Officer will present on Wednesday, April 15, 2015 at 3:40 p.m. Eastern Time at The Westin New York Grand Central Hotel in New York, NY.
CALA: 12.93 (-1.06)

3 Stocks Breaking Out on Unusual Volume
at The Street - Fri Mar 27, 12:56PM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
SWKS: 96.83 (+1.41), AXLL: 42.83 (-0.58), CALA: 12.93 (-1.06)

Calithera Biosciences (CALA) Crumbles: Stock Falls by 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 7:55AM CDT
Calithera Biosciences saw a big move last session, as the company’s shares fell by 7%. This reverses the recent trend for CALA as the stock is now up around 22%
LCI: 66.45 (-0.28), CALA: 12.93 (-1.06)

Calithera Biosciences reports FQ4 results
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:22PM CDT

CALA: 12.93 (-1.06)

Calithera Biosciences Reports Fourth Quarter and Full Year 2014 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 26, 3:05PM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today its financial results for the fiscal fourth quarter and year ended December 31, 2014. As of December 31, 2014, cash and cash equivalents totaled $102.0 million.
CALA: 12.93 (-1.06)

Pre-Earnings Calithera Biosciences Inc. Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Thu Mar 26, 6:00AM CDT
Calithera Biosciences Inc. (NASDAQ: CALA) based in San Francisco, CA a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer will be reporting fourth quarter and year-end earnings this morning. Anticipation of this release has driven the recent investor interest in the shares of Calithera. Rollercoaster - like activity was observed for the past 4 trading days.
CALA: 12.93 (-1.06)

Calithera Biosciences (CALA) Jumps: Stock Rises 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 7:51AM CDT
Calithera Biosciences, Inc. (CALA) was a big mover last session, as the company saw its shares rise roughly 19% on the day.
LCI: 66.45 (-0.28), CALA: 12.93 (-1.06)

Calithera Biosciences to Report Fourth Quarter and Year-End 2014 Financial Results on Thursday, March 26, 2015
GlobeNewswire - Fri Mar 20, 7:30AM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company's fourth quarter and year-end 2014 financial results will be released on Thursday, March 26, 2015. Company management will host a conference call on Thursday, March 26, 2015 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
CALA: 12.93 (-1.06)

Calithera Biosciences Announces Five Data Presentations at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Wed Mar 18, 3:30PM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA) a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced the upcoming presentation of five preclinical abstracts, highlighting the potential of CB-839, the Company's novel, orally bioavailable glutaminase inhibitor, at the American Association for Cancer Research, taking place April 18-22, 2015 in Philadelphia, Pennsylvania. Details for the two oral presentations and three poster presentations are as follows:
CALA: 12.93 (-1.06)

Calithera Biosciences (CALA) Jumps: Stock Moves Up 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 7:51AM CDT
Calithera Biosciences, Inc. (CALA) was a big mover last session, as the company saw its shares rise over 10% on the day.
LCI: 66.45 (-0.28), CALA: 12.93 (-1.06)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 8:15AM CST

NGL: 27.75 (+0.29), FNSR: 21.29 (-0.16), SSH: 4.18 (+0.04), YY: 61.86 (+1.12), CNAT: 6.31 (-0.15), ASTI: 1.07 (+0.04), CLDN: 13.59 (-2.77), AXN: 1.77 (+0.01), VMEM: 3.73 (-0.02), BLRX: 2.12 (unch), GENE: 4.88 (-0.05), OREX: 7.39 (+0.22), SKUL: 11.25 (+0.30), CALA: 12.93 (-1.06), AVEO: 2.04 (+0.12), MSO: 5.93 (-0.09), GALE: 1.39 (unch), CKP: 11.03 (-0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...